Lipid metabolic changes during hormonal treatment of endometriosis

Teichmann AT, A T Teichmann, P Cremer, Cremer P, Peter Cremer, H Wieland, Wieland H, Heinrich Wieland, Kuhn W, W. Kühn, W Kuhn, Seidel D, D Seidel
Maturitas · 1988 · vol. 10(1) , pp. 27–33 · doi:10.1016/0378-5122(88)90128-4 · PMID:2969446 · W1969227118
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated alterations in lipid metabolism in patients undergoing hormonal treatment for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Three groups of patients with pelvic endometriosis were treated with medroxyprogesterone acetate (MPA) 50 mg/day (n = 10), lynestrenol (LYN) 10 mg/day (n = 25) and danazol (DAN) 600 mg/day (n = 25) respectively. Total cholesterol, triglycerides, alpha-lipoprotein, prebetalipoprotein, beta-lipoprotein cholesterol, high-density (HDL) and low-density (LDL) lipoprotein and apolipoprotein A1 and B concentrations were determined before treatment and after 3 and 6 mth of therapy. Whereas lipid, lipoprotein and apolipoprotein levels did not change in the MPA group, the patients on LYN and in particular those on DNA showed marked changes in lipoportein patterns. Alpha-lipoprotein, HDL and apolipoprotein A1 levels fell, while beta-lipoprotein, LDL and apolipoprotein concentrations rose, these changes being statistically significant. No alterations were seen in the serum levels of cholesterol, triglycerides or prebetalipoprotein cholesterol. In view of a possible relationship between high LDL and low HDL levels and a risk of accelerated coronary arteriosclerosis in women it was concluded that progestogen-induced alterations in lipoprotein patterns should be avoided as far as long-term treatment is concerned and where additional risk factors are present.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Endometriosis Lipid Metabolism Lynestrenol Medroxyprogesterone Pelvic Neoplasms Pregnadienes Adult Apolipoprotein A-I Apolipoproteins A Apolipoproteins A Apolipoproteins B Apolipoproteins B Cholesterol Cholesterol Cholesterol, HDL Cholesterol, HDL Cholesterol, LDL Cholesterol, LDL Danazol

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (5)

SciLite annotations

chemicals 16
lipid medroxyprogesterone acetate lynestrenol danazol cholesterol triglyceride lipoprotein cholesterol lipoprotein lipid lipoprotein lipoprotein lipoprotein cholesterol triglyceride
organisms 1
noordeloos 2009062

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
unpaywall
last seen: 2026-07-27T06:55:32.580041+00:00
License: CC0 · commercial use OK